На главнуюОбразованиеПохожее видеоЕще от: VJOncology

Can atezolizumab succeed where BCG fails in bladder cancer?

Оценок: 0 | Просмотров: 24
BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some patients continue to have persistent high-grade disease long after treatment, prompting the development of new drugs such as atezolizumab. In this video, Peter Black, MD, of the University of British Colombia, Vancouver, Canada, discusses a clinical trial investigating the efficacy of atezolizumab in BCG-unresponsive bladder cancer (NCT02844816). This interview took place at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.
Категория: Образование
Html code for embedding videos on your blog
Текстовые комментарии ()

Хотите оставить комментарий?

Присоединитесь к YouTube, или войдите, если вы уже зарегистрированы.